The Latest Breaking News from Lilly

The tablet could be a cheaper and more convenient alternative to injections.

Shares in a pharmaceutical company plummeted after the results were made public

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s disease.

Breakthroughs that help us live longer, healthier lives can also create opportunities for investors.

An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific cholesterol-raising conditions.

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025